Vertex Pharmaceuticals (VRTX) Short term Debt (2009 - 2016)

Vertex Pharmaceuticals' Short term Debt history runs 6 years deep, the most recent figure standing at $75.0 million for Q4 2016.

• In Q4 2016, Short term Debt changed N/A year-over-year to $75.0 million; the TTM figure through Dec 2016 stood at $75.0 million (changed N/A YoY), while the FY2016 annual figure was $75.0 million, changed N/A from the prior year.
• Short term Debt for Q4 2016 stood at $75.0 million, down from $297.8 million in the prior quarter.
• The five-year high for Short term Debt was $297.8 million in Q3 2016, with the low at $14.2 million in Q4 2014.
• The 3-year median for Short term Debt is $75.0 million (2016), against an average of $118.0 million.
• Peak annual rise in Short term Debt reached 416.82% in 2016, while the deepest fall reached 412.68% in 2016.
• Vertex Pharmaceuticals' Short term Debt stood at $14.2 million in 2014, then surged by 201.8% to $42.9 million in 2015, then soared by 74.94% to $75.0 million in 2016.
• Business Quant data shows VRTX's Short term Debt at $75.0 million in Q4 2016, $297.8 million in Q3 2016, and $221.6 million in Q2 2016.